Production lost due to cervical cancer in Poland in 2012

Dubas‐Jakóbczyk, Katarzyna; Kocot, Ewa; Seweryn, Michał; Koperny, Magdalena

doi:10.13075/mp.5893.00378

Cited by 11 publications

(8 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other indirect costs were estimated using the human capital approach (S1 Table). The production losses were measured in both monetary and quantitative terms (e.g., days of productivity loss) [44]. The value of unpaid time devoted to own care and family defined caregivers [45].…”

Section: Methodsmentioning

confidence: 99%

The cost-effectiveness of controlling cervical cancer using a new 9-valent human papillomavirus vaccine among school-aged girls in Australia

2019

View full text Add to dashboard Cite

IntroductionCervical cancer imposes a substantial health burden worldwide including in Australia and is caused by persistent infection with one of 13 sexually transmitted high-risk human papillomavirus (HPV) types. The objective of this study was to assess the cost-effectiveness of adding a nonavalent new Gardasil-9® (9vHPV) vaccine to the national immunisation schedule in Australia across three different delivery strategies.Materials and methodsThe Papillomavirus Rapid Interface for Modelling and Economics (PRIME) model was used to examine the cost-effectiveness of 9vHPV vaccine introduction to prevent HPV infection. Academic literature and anecdotal evidence were included on the demographic variables, cervical cancer incidence and mortality, treatment costs, and vaccine delivery costs. The incremental cost-effectiveness ratios (ICERs) were measured per disability-adjusted life years (DALYs) averted, using the heuristic cost-effectiveness threshold defined by the World Health Organisation (WHO). Analyses and data from international agencies were used in scenario analysis from the health system and societal perspectives.ResultsThe 9vHPV vaccination was estimated to prevent 113 new cases of cervical cancer (discounted) during a 20-year period. From the health system and societal perspectives, the 9vHPV vaccination was very cost-effective in comparison with the status quo, with an ICER of A$47,008 and A$44,678 per DALY averted, respectively, using the heuristic cost-effectiveness threshold level. Considering delivery strategies, the ICERs per DALY averted were A$47,605, A$46,682, and A$46,738 for school, health facilities, and outreach-based vaccination programs from the health system perspective, wherein, from the societal perspective, the ICERs per DALY averted were A$46,378, A$43,729, A$43,930, respectively. All estimates of ICERs fell below the threshold level (A$73,267).ConclusionsThis cost-effectiveness evaluation suggests that the routine two-dose 9vHPV vaccination strategy of preadolescent girls against HPV is very cost-effective in Australia from both the health system and societal perspectives. If equally priced, the 9vHPV option is the most economically viable vaccine. Overall, this analysis seeks to contribute to an evidence-based recommendation about the new 9vHPV vaccination in the national immunisation program in Australia.

show abstract

Section: Methodsmentioning

confidence: 99%

The cost-effectiveness of controlling cervical cancer using a new 9-valent human papillomavirus vaccine among school-aged girls in Australia

2019

View full text Add to dashboard Cite

show abstract

“…Apart from the ethical aspect, Poland' s relatively low 5-year survival rate of CC has an economic context. In 2012 alone, CC incidence and the consequent mortality caused the loss of approximately 957,678 working days in Poland, and this resulted in production losses of EUR 111.4 million, 66% of which was related to mortality [27].…”

Section: Discussionmentioning

confidence: 99%

Secondary prevention and treatment of cervical cancer - update from Poland

Poniewierza

Śniadecki

Brzeziński

et al. 2022

Nowotwory. Journal of Oncology

View full text Add to dashboard Cite

Introduction. Cervical cancer is the 4 th most common cancer in terms of incidence and mortality in women worldwide. The aim of the study was to investigate and analyze the effects of Poland's publicly funded cervical cancer screening and treatment programs. Material and methods. The study analyzed the financial and epidemiological data provided by the Polish National Health Fund and the Polish National Cancer Registry on the prevention and treatment of cervical cancer in Poland in 2011-2017. Results. Our study identified a systematic reduction in the number of patients undergoing cervical cytology. Despite high levels of financial expenditure, no correlation was found between the total cost of benefits in PLN million (W = 0.911; p = 0.404) and mortality expressed by the standardized coefficient (W = 0.884; p = 0.243). Conclusions. Despite decreasing mortality rates in cases of cervical cancer in Poland, the organization and delivery of prevention and treatment programs should be considered insufficient.

show abstract

“…When we further examined health as human capital, an even greater loss was observed as much of it was attributed to productivity loss owing to the inequalities. A Polish study estimated a substantial level of CC-attributable annual productivity loss equivalent to approximately 702,964 working days lost or 111.4 million Euros due to women's disability and mortality (Dubas-Jakóbczyk et al, 2016).…”

Section: Discussionmentioning

confidence: 99%

Forgone Health and Economic Benefits Associated with Socioeconomic Differences in Organized Cervical Cancer Screening

Hsieh

Chen

Liu

et al. 2019

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Objective: To describe cervical cancer screening participation among women in Taiwan under its population-based screening policy and to estimate the economic burden of disease attributable to avoidable disparities in cervical cancer (CC) screening. Methods: We identified a nationally-representative sample of females aged 30 years or above who were eligible for Pap smear testing in Taiwan from 1 January to 31 December 2013. An administrative database with detailed claims of health care utilization under the universal coverage health care system was used. Socioeconomic position of the female subjects was defined using the occupation classification, and two groups were specifically identified: general (O1) and low-income (O5) groups. Differences in screening rate, CC prevalence, and CC-attributable deaths were assessed between the two groups. Economic consequences as a result of screening inequalities were estimated using actual total health care spending (health care expenditure), monetary value per life-year and years of life lost for ill health and screening disparities (health as consumption good), and productivity losses alongside costs of social benefits (health as capital good). Result: A total of 301,057 enrolled females aged 30 years and older eligible for screening were identified. Overall, 3-year and 1-year screening rates among all subjects were 0.601 and 0.372, respectively. Impact of observed differences in screening translated to US$59,568 of health care spending in one year, 90.4% of which was specific to hospital admissions. When we viewed health as a consumption good and capital good, the impact of screening disparity on health losses through CC would be equivalent to US$78,095 and US$190,868, respectively. Conclusion: Forgone health and economic benefits associated with inequalities in CC screening uptake can be considerable in productive women.

show abstract

Production lost due to cervical cancer in Poland in 2012

Cited by 11 publications

References 11 publications

The cost-effectiveness of controlling cervical cancer using a new 9-valent human papillomavirus vaccine among school-aged girls in Australia

The cost-effectiveness of controlling cervical cancer using a new 9-valent human papillomavirus vaccine among school-aged girls in Australia

Secondary prevention and treatment of cervical cancer - update from Poland

Forgone Health and Economic Benefits Associated with Socioeconomic Differences in Organized Cervical Cancer Screening

Contact Info

Product

Resources

About